Fuhong Hanlin (02696.HK) announced that the company has entered into a cooperation and licensing agreement with Palleon Pharmaceuticals Inc. ("Palleon") on June 28, 2022. Palleon and the company agreed to use their respective proprietary technologies to and patents, regarding Palleon's product bifunctional HER2-sialidase fusion protein, and another tumor-related target to be jointly developed by both parties - sialidase bifunctional fusion protein (the "Collaborative Development Product", together with the bifunctional HER2-sialidase fusion protein). Sialidase fusion proteins, collectively referred to as "licensed products") are used for the global collaborative development of human disease treatment ("Field") and in their respective licensed areas (the company's licensed area: China (including Hong Kong, Macao and Taiwan); Palleon's licensed area: except the Production and commercialization arrangements are made globally outside the company's licensed territories.
As of the close of trading on June 28, 2022, Henlius (02696.HK) closed at 17.92 yuan, down 1.65%, with a turnover rate of 0.06%, a trading volume of 90,200 shares, and a transaction volume of 1.5966 million yuan. Investment banks have mainly rated the stock as buy. In the past 90 days, a total of 1 investment bank has given a buy rating , and the average target price in the past 90 days is 28.73. The latest research report from First Shanghai gave Fuhong Hanlin a buy rating and a target price of 28.73.
Institutional rating details are shown in the table below:
Fuhong Hanlin has a market value of 2.978 billion yuan, ranking 35th in the biological products II industry. The main indicators are shown in the table below:
The above content is compiled by Securities Star based on public information. If you have any questions, please contact us.
